Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Bornstein, Jacob and Roux, Surita and Petersen, Lone Kjeld and Huang, Li-Min and Dobson, Simon R. and Pitisuttithum, Punnee and Diez-Domingo, Javier and Schilling, Andrea and Ariffin, Hany Mohd and Tytus, Richard and Rupp, Richard and Senders, Shelly and Engel, Eli and Ferris, Daron and Kim, Yae-Jean and Kim, Young Tae and Kurugol, Zafer and Bautista, Oliver and Nolan, Katrina M. and Sankaranarayanan, Sandhya and Saah, Alfred and Luxembourg, Alain (2021) Three-year follow-up of 2-dose versus 3-dose HPV vaccine. Pediatrics, 147 (1). ISSN 0031-4005, DOI

Full text not available from this repository.


Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 0, 6]: n = 301; months 0 and 12 0, 12]: n = 151) or 3 doses (months 0,2, and 6 0, 2, 6]: n = 301); boys received 2 doses (0, 6]: n = 301; 0, 12]: n = 150); and young women received 3 doses (0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose.

Item Type: Article
Funders: Merck & Company
Uncontrolled Keywords: Human-Papillomavirus;Vaccine16/18;Age 9-14 years;Genotype
Subjects: R Medicine
R Medicine > RJ Pediatrics
Divisions: Faculty of Medicine
Depositing User: Ms Zaharah Ramly
Date Deposited: 18 Sep 2022 11:02
Last Modified: 18 Sep 2022 11:02

Actions (login required)

View Item View Item